Infectious complications after transrectal prostate biopsy in Algeria: A prospective study in a high-resistance setting

IF 4 2区医学 Q2 UROLOGY & NEPHROLOGY

Prostate International Pub Date : 2026-09-01 Epub Date: 2026-05-15 DOI:10.1016/j.prnil.2026.05.001

Samir Bouras

{"title":"Infectious complications after transrectal prostate biopsy in Algeria: A prospective study in a high-resistance setting","authors":"Samir Bouras","doi":"10.1016/j.prnil.2026.05.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The aim of this study was to assess infectious outcomes and safety of fosfomycin trometamol compared with ciprofloxacin for the prevention of infectious complications following transrectal ultrasound–guided prostate biopsy (TRPB) in a local setting characterized by high fluoroquinolone resistance.</div></div><div><h3>Material and methods</h3><div>This prospective single-center cohort study included 423 consecutive patients undergoing TRPB between February 2023 and December 2025. An initial comparative phase involved 200 patients receiving either ciprofloxacin (n=83) or fosfomycin trometamol (n=117). Fosfomycin was subsequently adopted as the standard prophylactic regimen in an additional 223 patients. Infectious complications occurring within 30 days were recorded. A univariate analysis was performed to explore factors associated with infectious complications.</div></div><div><h3>Results</h3><div>The overall rate of infectious complications was 8.3% (35/423), mainly transient isolated fever (5.2%). Five patients (1.2%) required hospitalization for acute prostatitis. No statistically significant association with infectious complications was observed in the univariate analysis. In the initial comparative phase, no significant difference was observed between ciprofloxacin and fosfomycin regarding infectious outcomes.</div></div><div><h3>Conclusions</h3><div>In a context of high fluoroquinolone resistance, single-dose fosfomycin trometamol may represent a pragmatic prophylactic option, although comparative efficacy cannot be concluded from the present design.</div></div><div><h3>Level of Evidence</h3><div>Level 2.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 3","pages":"Pages 260-263"},"PeriodicalIF":4.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate International","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2287888226000346","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The aim of this study was to assess infectious outcomes and safety of fosfomycin trometamol compared with ciprofloxacin for the prevention of infectious complications following transrectal ultrasound–guided prostate biopsy (TRPB) in a local setting characterized by high fluoroquinolone resistance.

Material and methods

This prospective single-center cohort study included 423 consecutive patients undergoing TRPB between February 2023 and December 2025. An initial comparative phase involved 200 patients receiving either ciprofloxacin (n=83) or fosfomycin trometamol (n=117). Fosfomycin was subsequently adopted as the standard prophylactic regimen in an additional 223 patients. Infectious complications occurring within 30 days were recorded. A univariate analysis was performed to explore factors associated with infectious complications.

Results

The overall rate of infectious complications was 8.3% (35/423), mainly transient isolated fever (5.2%). Five patients (1.2%) required hospitalization for acute prostatitis. No statistically significant association with infectious complications was observed in the univariate analysis. In the initial comparative phase, no significant difference was observed between ciprofloxacin and fosfomycin regarding infectious outcomes.

Conclusions

In a context of high fluoroquinolone resistance, single-dose fosfomycin trometamol may represent a pragmatic prophylactic option, although comparative efficacy cannot be concluded from the present design.

Level of Evidence

Level 2.

查看原文本刊更多论文

阿尔及利亚经直肠前列腺活检后的感染并发症：一项高阻力环境下的前瞻性研究

本研究的目的是评估磷霉素曲美他醇与环丙沙星在经直肠超声引导前列腺活检（TRPB）后感染并发症的预防效果和安全性，该活检在局部环境中具有高氟喹诺酮类药物耐药性。材料和方法本前瞻性单中心队列研究纳入了423例在2023年2月至2025年12月期间连续接受TRPB治疗的患者。初始比较阶段包括200例接受环丙沙星（83例）或磷霉素曲美他醇（117例）治疗的患者。磷霉素随后在另外223名患者中被采用作为标准预防方案。记录30天内发生的感染并发症。进行单因素分析以探讨与感染并发症相关的因素。结果感染性并发症发生率为8.3%(35/423)，以短暂性孤立性发热为主（5.2%）。5例患者（1.2%）因急性前列腺炎需要住院治疗。在单变量分析中未观察到与感染并发症有统计学意义的关联。在最初的比较阶段，没有观察到环丙沙星和磷霉素在感染结局方面的显著差异。结论在高氟喹诺酮耐药的情况下，单剂量磷霉素曲美他莫可能是一种实用的预防选择，尽管目前的设计还不能得出比较疗效。证据等级：2级。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate International Medicine-Urology

CiteScore

4.40

自引率

26.70%

发文量

审稿时长

35 days

期刊介绍： Prostate International (Prostate Int, PI), the official English-language journal of Asian Pacific Prostate Society (APPS), is an international peer-reviewed academic journal dedicated to basic and clinical studies on prostate cancer, benign prostatic hyperplasia, prostatitis, and ...